Skip to main content
Log in

Ibandronic acid unlikely choice for IBD-related fracture prevention

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König H-H.Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. PharmacoEconomics 26: 311-328, No. 4, Jan 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ibandronic acid unlikely choice for IBD-related fracture prevention. Pharmacoecon. Outcomes News 551, 6 (2008). https://doi.org/10.2165/00151234-200805510-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805510-00015

Keywords

Navigation